难治性类风湿关节炎的医疗资源利用与经济学负担:一项疾病成本研究
该研究纳入52例符合EULAR定义的难治性RA(D2T RA)和100例非D2T RA患者,通过问卷和电子病历回顾收集医疗资源利用与工作生产力数据。D2T RA患者年均总成本为€37 605(95%CI €27 689-€50 378),显著高于非D2T RA的€19 217(95%CI €15 647-€22 945)(P<0.001)。校正HAQ后,D2T RA与更高总成本的关联不再具有统计学显著性,HAQ是唯一独立决定因素。
要点
- D2T RA患者年均总成本显著高于非D2T RA患者(P<0.001)。
- D2T RA患者更频繁就诊风湿科、更多入住日间病房、更多实验室检查及更多药物使用(P<0.01)。
- 校正身体功能(HAQ)后,D2T RA与更高总成本的关联不再显著,HAQ是唯一独立决定因素。
核心结论
- D2T RA的经济负担显著高于非D2T RA,表现为更高的医疗资源利用和更高的年均总成本。
- 功能残疾是RA更高成本的关键决定因素。
研究设计与样本
- 疾病成本研究,纳入52例符合EULAR定义的D2T RA患者和100例非D2T RA患者。
- 通过问卷和电子病历回顾在研究访视期间收集医疗资源利用、其他资源利用和工作生产力数据,计算年成本并进行组间比较。
- 采用多变量线性回归分析评估D2T RA是否与更高成本相关。
主要发现
- D2T RA患者年均总成本为€37 605(95%CI €27 689-€50 378),非D2T RA患者为€19 217(95%CI €15 647-€22 945)(P<0.001)。
- D2T RA患者更频繁就诊风湿科、更常入住日间病房、接受更多实验室检查并使用更多药物(尤其是靶向合成DMARDs),与非D2T RA患者相比(P<0.01)。
- D2T RA患者总成本的主要贡献者为家人和朋友的非正式帮助(28%)、药物(26%)和工作生产力损失(16%)。
- 校正身体功能(HAQ)后,D2T RA与更高总成本的关联不再具有统计学显著性。
- 多变量分析中HAQ是更高成本的唯一独立决定因素。
临床怎么用
- D2T RA患者医疗资源利用和成本显著更高,临床管理需关注功能残疾以控制经济负担。
- 改善身体功能(HAQ)可能有助于降低RA患者的总体成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the impact of difficult-to-treat rheumatoid arthritis (D2T RA) on (costs related to) healthcare utilization, other resource use and work productivity. METHODS: Data regarding healthcare utilization, other resource use and work productivity of 52 D2T (according to the EULAR definition) and 100 non-D2T RA patients were collected via a questionnaire and an electronic patient record review during a study visit. Annual costs were calculated and compared between groups. Multivariable linear regression analysis was performed to assess whether having D2T RA was associated with higher costs. RESULTS: Mean (95% CI) annual total costs were €37 605 (€27 689 - €50 378) for D2T and €19 217 (€15 647 - €22 945) for non-D2T RA patients (P<0.001). D2T RA patients visited their rheumatologist more frequently, were more often admitted to day-care facilities, underwent more laboratory tests and used more drugs (specifically targeted synthetic DMARDs), compared with non-D2T RA patients (P<0.01). In D2T RA patients, the main contributors to total costs were informal help of family and friends (28%), drugs (26%) and loss of work productivity (16%). After adjustment for physical functioning (HAQ), having D2T RA was no longer statistically significantly associated with higher total costs. HAQ was the only independent determinant of higher costs in multivariable analysis. CONCLUSIONS: The economic burden of D2T RA is significantly higher than that of non-D2T RA, indicated by higher healthcare utilization and higher annual total costs. Functional disability is a key determinant of higher costs in RA.
引用
- Roodenrijs NMT, Welsing PMJ, van der Goes MC, et al. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology (Oxford). 2021. PMID: 33502493. doi:10.1093/rheumatology/keab078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。